Showing results (141-150 of 158) with videos related to
Sort By:
Pageof 16
Leukemia & Lymphoma|April 25, 2007
Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failureAshley P Ng, Andrew Wirth, John F Seymour, et al.Cancers|April 23, 2020
Durable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation TherapyMichael P MacManus, Rodney J Hicks, Mathias Bressel, et al.Leukemia & Lymphoma|November 6, 2012
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myelomaNicole Wong Doo, Philip A Thompson, H Miles Prince, et al.Leukemia & Lymphoma|November 17, 2006
Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphomaMax Wolf, Mark Bentley, Paula Marlton, et al.Science Advances|July 30, 2025
Better and faster decisions by larger fish shoals in the wildKorbinian Pacher, David Bierbach, Yunus Sevinchan, et al.Blood|July 10, 2008
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)Graham M Mead, Sharon L Barrans, Wendi Qian, et al.Leukemia & Lymphoma|October 15, 2015
Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacyThomas E Lew, Chan Y Cheah, Dennis A Carney, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup studyMarinus H J van Oers, Martine Van Glabbeke, Livia Giurgea, et al.Leukemia & Lymphoma|February 15, 2011
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology GroupAndrew Wirth, Andrew Grigg, Max Wolf, et al.Leukemia & Lymphoma|January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemiaMasa Lasica, Abbey Willcox, Kate Burbury, et al.Pageof 16